dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Delta subfamily (type: enzyme)
Target: protein kinase C theta

Ligand: 10-Me-Aplog-1 (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity: 9.270000457763672 pKi
Reference (Journal): Structure-activity studies on the spiroketal moiety of a simplified analogue of debromoaplysiatoxin with antiproliferative activity.
Published in: J Med Chem

Ligand: aplithianine A (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.440000057220459 pIC50
Reference (Journal): Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases.
Published in: J Nat Prod

Ligand: CC-90005 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pIC50
Reference (Journal): Discovery of the Selective Protein Kinase C-&#x3b8; Kinase Inhibitor, CC-90005.
Published in: J Med Chem

Ligand: compound 41 [PMID: 25000588] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.639999866485596 pIC50
Reference (Journal): Discovery of selective and orally bioavailable protein kinase Cθ (PKCθ) inhibitors from a fragment hit.
Published in: J Med Chem

Ligand: darovasertib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.399999618530273 pIC50
Reference (Patent): Protein kinase C inhibitors and methods of their use

Ligand: GSK690693 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pIC50
Reference (Journal): Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase.
Published in: J Med Chem

Ligand: PKCθ inhibitor 14 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.600000381469727 pIC50
Reference (Journal): Discovery and optimization of 1,7-disubstituted-2,2-dimethyl-2,3-dihydroquinazolin-4(1H)-ones as potent and selective PKCθ inhibitors.
Published in: Bioorg Med Chem

Ligand: sotrastaurin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9 pIC50
Reference (Journal): Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes.
Published in: J Med Chem
Target family: Diacylglycerol kinases (type: enzyme)
Target: diacylglycerol kinase alpha

Ligand: BMS-502 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.34000015258789 pIC50
Reference (Journal): Discovery of Potent, Dual-Inhibitors of Diacylglycerol Kinases Alpha and Zeta Guided by Phenotypic Optimization.
Published in: ACS Med Chem Lett

Ligand: BMS-684 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.820000171661377 pIC50
Reference (Journal): Discovery of Potent, Dual-Inhibitors of Diacylglycerol Kinases Alpha and Zeta Guided by Phenotypic Optimization.
Published in: ACS Med Chem Lett
Target family: Diacylglycerol kinases (type: enzyme)
Target: diacylglycerol kinase zeta

Ligand: BMS-502 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.680000305175781 pIC50
Reference (Journal): Discovery of Potent, Dual-Inhibitors of Diacylglycerol Kinases Alpha and Zeta Guided by Phenotypic Optimization.
Published in: ACS Med Chem Lett
Target family: Dimethylarginine dimethylaminohydrolases (type: enzyme)
Target: <i>N</i><sup>G</sup>,<i>N</i><sup>G</sup>-Dimethylarginine dimethylaminohydrolase 1

Ligand: compound 2e [PMID: 19013076] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.699999809265137 pKi
Reference (Journal): Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads.
Published in: Bioorg Med Chem
Target family: DNA glycosylases (type: enzyme)
Target: 8-oxoguanine DNA glycosylase

Ligand: TH5487 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Small-molecule inhibitor of OGG1 suppresses proinflammatory gene expression and inflammation.
Published in: Science
Target family: DNA polymerases (type: enzyme)
Target: DNA polymerase beta

Ligand: oleanolic acid (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.599999904632568 pIC50
Reference (Journal): Inhibitors of DNA polymerase beta: activity and mechanism.
Published in: Bioorg Med Chem
Target family: DNA polymerases (type: enzyme)
Target: DNA polymerase theta

Ligand: ART558 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pIC50
Reference (Journal): Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta.
Published in: J Med Chem

Ligand: ART812 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.119999885559082 pIC50
Reference (Journal): Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta.
Published in: J Med Chem

Ligand: RP-6685 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.239999771118164 pIC50
Reference (Journal): Identification of <b>RP-6685</b>, an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Pol&#x3b8;.
Published in: J Med Chem
Target family: DNA topoisomerases (type: enzyme)
Target: DNA topoisomerase I

Ligand: compound 19 [PMID: 7707314] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.550000190734863 pIC50
Reference (Journal): Synthesis, topoisomerase I inhibitory activity, and in vivo evaluation of 11-azacamptothecin analogs.
Published in: J Med Chem

Ligand: compound 5z [PMID: 8410981] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.570000171661377 pIC50
Reference (Journal): Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs.
Published in: J Med Chem

Ligand: irinotecan (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1996), EMA (2016)
Primary target: yes
Median affinity:  -
Reference (Journal): Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38.
Published in: J Pharmacol Exp Ther

Ligand: irinotecan (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1996), EMA (2016)
Primary target: yes
Median affinity:  -
Reference (Journal): Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials.
Published in: J Natl Cancer Inst

Ligand: (S)-DRF-1042 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity:  -
Reference (Patent): Pharmaceutical compositions of [5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin.
Target family: DNA topoisomerases (type: enzyme)
Target: DNA topoisomerase II alpha

Ligand: doxorubicin (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1974), EMA (1996)
Primary target: no
Median affinity: 6 pIC50
Reference (Journal): Isoaurostatin, a novel topoisomerase inhibitor produced by Thermomonospora alba.
Published in: J Nat Prod

Ligand: etoposide (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1983)
Primary target: yes
Median affinity: 7.300000190734863 pIC50

Ligand: mitoxantrone (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1987)
Primary target: no
Median affinity: 5.28000020980835 pIC50
Reference (Journal): The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds.
Published in: Bioorg Med Chem

Ligand: teniposide (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1992)
Primary target: no
Median affinity:  -
Reference (Journal): Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II.
Published in: Biochemistry
Target family: Dopamine receptors (type: gpcr)
Target: D<sub>2</sub> receptor

Ligand: quinpirole (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors.
Published in: Eur J Pharmacol
Target family: Dopamine receptors (type: gpcr)
Target: D<sub>2</sub> receptor

Ligand: 7-OH-DPAT (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.2 pKi
Reference (Journal): Iodinated 2-aminotetralins and 3-amino-1-benzopyrans: ligands for dopamine D2 and D3 receptors.
Published in: J Med Chem

Ligand: 7-OH-DPAT (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Lack of discrimination by agonists for D2 and D3 dopamine receptors.
Published in: Neuropsychopharmacology

Ligand: 7-OH-DPAT (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Characterization of the human dopamine D3 receptor expressed in transfected cell lines.
Published in: Eur J Pharmacol
Target family: Dopamine receptors (type: gpcr)
Target: D<sub>3</sub> receptor

Ligand: pergolide (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1988)
Primary target: no
Median affinity: 8.300000190734863 pKi
Reference (Journal): Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor.
Published in: Eur J Pharmacol
Target family: Dual specificity phosphatases (type: enzyme)
Target: protein tyrosine phosphatase 4A3

Ligand: JMS-053 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.699999809265137 pIC50
Reference (Journal): The dual inhibition against the activity and expression of tyrosine phosphatase PRL-3 from a rhodanine derivative.
Published in: Bioorg Med Chem Lett
Target family: Dyrk1 subfamily (type: enzyme)
Target: dual specificity tyrosine phosphorylation regulated kinase 1B

Ligand: AZ191 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.769999980926514 pIC50
Reference (Journal): Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesis.
Published in: J Med Chem

Ligand: compound 17 [PMID: 23642479] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.149999618530273 pIC50
Reference (Journal): Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315.
Published in: Bioorg Med Chem Lett

Ligand: compound 3b [PMID: 23454515] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.139999866485596 pIC50
Reference (Journal): Chemical synthesis and biological validation of immobilized protein kinase inhibitory Leucettines.
Published in: Eur J Med Chem

Ligand: compound 68 [PMID: 24900699] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.619999885559082 pIC50
Reference (Journal): Tricyclic Pyrimidines As Inhibitors of DYRK1A/DYRK1B As Potential Treatment for Down's Syndrome or Alzheimer's Disease.
Published in: ACS Med Chem Lett

Ligand: compound 72 [WO2013026806] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.550000190734863 pIC50
Reference (Patent): Dyrk1 inhibitors and uses thereof.

Ligand: harmine (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.78000020980835 pIC50
Reference (Journal): Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation.
Published in: FEBS J

Ligand: voruciclib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.03000020980835 pIC50
Reference (Journal): Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells.
Published in: PLoS ONE
Target family: Dyrk1 subfamily (type: enzyme)
Target: dual specificity tyrosine phosphorylation regulated kinase 4

Ligand: leucettine L41 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.28000020980835 pIC50
Reference (Journal): Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.
Published in: J Med Chem
Target family: Dyrk2 subfamily (type: enzyme)
Target: dual specificity tyrosine phosphorylation regulated kinase 2

Ligand: compound 3b [PMID: 23454515] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.889999866485596 pIC50
Reference (Journal): Chemical synthesis and biological validation of immobilized protein kinase inhibitory Leucettines.
Published in: Eur J Med Chem

Ligand: compound 5b [PMID: 24900464] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.21999979019165 pIC50
Reference (Journal): Potent and Selective Inhibitors of CK2 Kinase Identified through Structure-Guided Hybridization.
Published in: ACS Med Chem Lett

Ligand: leucettine L41 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.460000038146973 pIC50
Reference (Journal): Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing.
Published in: J Med Chem
Target family: Dyrk2 subfamily (type: enzyme)
Target: dual specificity tyrosine phosphorylation regulated kinase 3

Ligand: compound 1a [PMID: 24900749] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.150000095367432 pIC50
Reference (Journal): Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo.
Published in: ACS Med Chem Lett

Ligand: compound 20 [PMID: 30998356] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.980000019073486 pIC50
Reference (Journal): Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy.
Published in: J Med Chem

Ligand: compound 3b [PMID: 23454515] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.739999771118164 pIC50
Reference (Journal): Chemical synthesis and biological validation of immobilized protein kinase inhibitory Leucettines.
Published in: Eur J Med Chem

Ligand: kinase inhibitor 2 [PMID: 30199702] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.420000076293945 pIC50
Reference (Journal): A β-glucuronidase-responsive albumin-binding prodrug for potential selective kinase inhibitor-based cancer chemotherapy.
Published in: Eur J Med Chem
Target family: E2 ubiquitin-conjugating enzymes (type: enzyme)
Target: ubiquitin conjugating enzyme E2 D1

Ligand: EN450 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Chemoproteomics-enabled discovery of a covalent molecular glue degrader targeting NF-&#x3ba;B.
Published in: Cell Chem Biol
Target family: E2 ubiquitin-conjugating enzymes (type: enzyme)
Target: ubiquitin conjugating enzyme E2 D2

Ligand: EN67 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Targeted Protein Degradation through E2 Recruitment
Published in: bioRxiv
Target family: E3 ubiquitin ligase components (type: enzyme)
Target: Cbl proto-oncogene B

Ligand: NX-1607 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Patent): Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof
Target family: E3 ubiquitin ligase components (type: enzyme)
Target: DDB1 and CUL4 associated factor 1

Ligand: compound 13 [PMID: 37465299] (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.510000228881836 pKd
Reference (Journal): Discovery of New Binders for DCAF1, an Emerging Ligase Target in the Targeted Protein Degradation Field.
Published in: ACS Med Chem Lett

Ligand: OICR-8268 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.420000076293945 pKd
Reference (Journal): Discovery of Nanomolar DCAF1 Small Molecule Ligands.
Published in: J Med Chem

Ligand: YT47R (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Targeted Protein Degradation by Electrophilic PROTACs that Stereoselectively and Site-Specifically Engage DCAF1.
Published in: J Am Chem Soc
Target family: E3 ubiquitin ligase components (type: enzyme)
Target: F-box protein 3

Ligand: BC-1215 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.639999866485596 pIC50
Reference (Patent): Compositions and methods for treating respiratory injury or disease
Target family: E3 ubiquitin ligase components (type: enzyme)
Target: kelch domain containing 2

Ligand: KYH1872 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pKd
Reference (Journal): Targeted kinase degradation via the KLHDC2 ubiquitin E3 ligase.
Published in: Cell Chem Biol
Target family: E3 ubiquitin ligase components (type: enzyme)
Target: MDM2 proto-oncogene

Ligand: AMG-232 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 10.350000381469727 pKd
Reference (Journal): Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.
Published in: J Med Chem

Ligand: JN122 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 9.149999618530273 pKi
Reference (Journal): Discovery of JN122, a Spiroindoline-Containing Molecule that Inhibits MDM2/p53 Protein-Protein Interaction and Exerts Robust In Vivo Antitumor Efficacy.
Published in: J Med Chem

Ligand: milademetan (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 8.25 pIC50
Reference (Journal): The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy.
Published in: Eur J Med Chem

Ligand: milademetan (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 8.25 pIC50
Reference (Journal): Molecular docking of DS-3032B, a mouse double minute 2 enzyme antagonist with potential for oncology treatment development.
Published in: World J Clin Oncol

Ligand: RG7112 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.
Published in: ACS Med Chem Lett
Target family: E3 ubiquitin ligase components (type: enzyme)
Target: S-phase kinase associated protein 2

Ligand: compound 14i [PMID: 37204466] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.5600004196167 pIC50
Reference (Journal): Discovery of Novel 1,3-Diphenylpyrazine Derivatives as Potent S-Phase Kinase-Associated Protein 2 (Skp2) Inhibitors for the Treatment of Cancer.
Published in: J Med Chem
Target family: E3 ubiquitin ligase components (type: enzyme)
Target: STIP1 homology and U-box containing protein 1

Ligand: peptide 22d (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 6.28000020980835 pKd
Reference (Journal): Discovery and Structure-Based Design of Macrocyclic Peptides Targeting STUB1.
Published in: J Med Chem
Target family: E3 ubiquitin ligase components (type: enzyme)
Target: von Hippel-Lindau tumor suppressor

Ligand: MS8815 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 6.699999809265137 pKd
Reference (Journal): Targeting Triple-Negative Breast Cancer by a Novel Proteolysis Targeting Chimera Degrader of Enhancer of Zeste Homolog 2.
Published in: ACS Pharmacol Transl Sci
Target family: eEF2K subfamily (type: enzyme)
Target: eukaryotic elongation factor 2 kinase

Ligand: compound 34 [PMID: 20189382] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.769999980926514 pIC50
Reference (Journal): Inhibition of eEF2-K by thieno[2,3-b]pyridine analogues.
Published in: Bioorg Med Chem Lett
Target family: EF-hand domain containing proteins (type: other_protein)
Target: RAS guanyl releasing protein 1

Ligand: RasGRP activator 1 (Synthetic organic)
Interaction type: Activator
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 9.600000381469727 pKi
Reference (Journal): Synthesis, biological, and biophysical studies of DAG-indololactones designed as selective activators of RasGRP.
Published in: Bioorg Med Chem
Target family: EF-hand domain containing proteins (type: other_protein)
Target: nucleobindin 1

Ligand: MJN228 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity: 5.480000019073486 pIC50
Reference (Journal): A Global Map of Lipid-Binding Proteins and Their Ligandability in Cells.
Published in: Cell

Ligand: KML110 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5.019999980926514 pIC50
Reference (Journal): A Global Map of Lipid-Binding Proteins and Their Ligandability in Cells.
Published in: Cell